<div id="readability-page-1"><div><p>China's pharma sector, once the go-to for cheap generics, is shifting to innovation and better quality. Key reforms and global ties drive this change. In 2024, revenues reached 80.4 billion US dollars, with forecasts to hit USD 126.6bn by 2030 at a steady 7.8% CAGR, making it the world's second largest market after the US.</p><p> Ahead, biologics and biosimilars will grow fastest, topping traditional drugs. As aging population boosts demand and global partnerships expand, China is set to move from generics factory to R&amp;D powerhouse, boosting its global role for investors eyeing steady growth.</p><p> Founded in 2011, Innovent Biologics stands at the forefront of China's biopharma evolution, delivering high-quality, affordable biopharmaceuticals to patients worldwide, targeting cancer, cardiovascular, metabolic, autoimmune, and eye diseases.</p><p> Its portfolio includes 18 launched products, complemented by four assets in Phase III or pivotal trials and 15 molecules in early clinical stages. Through partnerships with over 30 global leaders like Lilly, Sanofi, and MD Anderson, Innovent Biologics advances from discovery to commercialization, steadily bridging unmet needs for transformative care.</p><p> As 2025 drew to a close, Innovent Biologics achieved a defining milestone: TABOSUN® (ipilimumab N01), China's first domestically developed anti-CTLA-4 monoclonal antibody, gained NMPA approval. Combined with TYVYT® (sintilimab), it became the world's first approved dual-immunotherapy for neoadjuvant treatment of stage IIB-III resectable MSI-H/dMMR colon cancer, delivering 82% pathological complete response rates in Phase 3 NeoShot trials and allowing most patients to forgo postoperative chemotherapy.</p><p> Supported by rigorous data, this regime addresses a vital unmet need, reshaping colon cancer standards and affirming the company's stature in global immuno-oncology innovation.</p><h2> Revenue rockets in Q3</h2><p> In the high-stakes arena of biopharma, Innovent Biologics scripted a triumphant chapter in Q3 25, shattering 3.3 billion Chinese Yuan in product revenue with a thunderous nearly 40% y/y surge.</p><p> The driving force behind this success includes TYVYT, a well-established oncology drug, along with new cancer treatments and innovative biomedicines such as mazdutide, SINTBILO, and SYCUME. These products have benefited from effective market access and outreach strategies.</p><p> Mazdutide, in particular, received approval from China's National Medical Products Administration (NMPA) for treating type 2 diabetes, opening up new opportunities for the company. With 16 approved products and a promising pipeline, Innovent Biologics is poised for continued prosperity and global breakthroughs, marking 2025 as a pivotal year in its journey.</p><h2> Analysts bet big</h2><p> Fueled by unwavering execution, Innovent Biologics' stock rocketed 163.4% over the past one year, propelling its market capitalization to CNY 137.5bn amid a series of triumphs in 2025. The stock is currently trading at a forward P/E ratio of 43x based on projected 2026 earnings. </p><p> Analysts are overwhelmingly optimistic about the company's future, with 27 Buy ratings and only 2 Hold ratings. The consensus target price stands at CNY 100.3, indicating a potential upside of 25.5% from current levels. This bullish sentiment is driven by confidence in Innovent Biologics' robust pipeline and its ability to disrupt the biopharma industry.</p><h2> Execution risks ahead</h2><p> As Innovent Biologics surges from China's biopharma landscape, forging breakthroughs, amid oncology triumphs and metabolic moonshots, its ascent mirrors a dragon awakening. Significant inclusions broaden access; partnerships with titans like Lilly fortify its arsenal, and a pipeline teeming with promise signals enduring momentum.</p><p>Yet shadows loom: regulatory headwinds, patent cliffs, pricing pressures from volume-based procurement, and fierce rivalry in crowded immuno-oncology and GLP-1 arenas could test resolve. Execution risks linger in scaling global ambitions amid geopolitical currents. Still, with innovation as compass and patient needs as north star, Innovent Biologics navigates toward transformative impact, rewarding patient investors who embrace the biopharma frontier's exhilarating volatility.</p></div></div>

信達生物

<p>信達生物正在成為中國生物製藥行業的領導者，正從仿製藥轉向創新生物製藥。預計到 2030 年，公司收入將達到 1266 億美元，已推出 18 種產品，並擁有強大的產品 pipeline。在 2025 年第三季度，公司報告了 40% 的同比收入增長，主要得益於成功的腫瘤藥物。分析師們持樂觀態度，普遍目標價顯示出潛在的 25.5% 的上漲空間。然而，監管壓力和競爭等挑戰依然存在。信達生物對創新的關注使其在全球生物製藥領域具備顯著增長的潛力</p>

信達生物：生物製藥行業的冉冉新星